Tags |
|
|
Links |
|
|
E-Articles - Alzheimers Disease - What Is It?
Alzheimers disease is a form of dementia which affects middle-aged and older people. It is a progressive d
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
isease that slowly kills the victims nerve cells in the brain. Alzheimers is a rather complex disease that
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
seems to be caused by several influences.
It is the most common type of dementia, accounting for roughly
It is the most common type of dementia, accounting for roughly
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
seventy percent of diagnosed cases, and it knows no boundries, being spread across different cultures and
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
affecting both males and females in equal measure.
Alzheimers disease can be extremely stressful for the
Alzheimers disease can be extremely stressful for the
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
victims family, who very often find themselves being in the front line when it comes to providing care and
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
support. It ought to be remembered that the family member or members doing the caring will also need plen
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
ty of support.
The care of a Alzheimers patient is quite a challenge because the decline is slow and unpr
The care of a Alzheimers patient is quite a challenge because the decline is slow and unpr
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
edictable and can progress at a different pace. If it happens that Alzheimers is diagnosed, seek out any l
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ocal services and aid groups that are available from your doctor's surgery or inquire at your local hospit
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
l.
There is not a single special test for Alzheimers, but invariably the correct diagnosis is achieved by
There is not a single special test for Alzheimers, but invariably the correct diagnosis is achieved by
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
ruling out other causes of memory loss, for example: Parkinson’s disease, minor strokes, or depression.
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
This disease normally rears it's ugly head after the age of 60 or so, and the risk gets higher with age pr
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
ogression. All the same, it must be remembered that Alzheimers disease is not neccersarily a normal part o
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
f the aging process.
Alzheimers can be described as the death of the mind before the Body, and as such is
Alzheimers can be described as the death of the mind before the Body, and as such is
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
a very difficult and depressing condition for any family to have to deal with. Alzheimers is reckoned to b
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
e a fatal disease, but the usual cause of death is normally another illness (like pneumonia) which can dev
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
elop as a complication in an individual already severely weakened by Alzheimers.
The treatment of Alzheim
The treatment of Alzheim
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
ers Disease is still relatively young, but researchers are very confident that the time is not too far awa
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
y when medications will become available that will be able to successfully treat the symptoms of Azheimers
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.e-article.org.ua/article/241526/e-article-Alzheimers-Disease--What-Is-It.html">Alzheimers Disease - What Is It?</a>
BB link (for phorums):
[url=http://www.e-article.org.ua/article/241526/e-article-Alzheimers-Disease--What-Is-It.html]Alzheimers Disease - What Is It?[/url]
Related Articles:
No Documents No Delays - Avail No Fax Payday Loans
Bookmark it:
|